Roll over icons to start

P + 0

ANNUAL REPORT 2010

Skip Navigation Links
Home
Overview
Management Discussion and Analysis
Sustainable Development
Corporate Governance Statement
Directors' Report
Financial Report
Additional Information
List of Abbreviations
Shareholder Reporting Timetable
Corporate Directory

You are here:

Skip Navigation LinksSustainable Development > Social Responsibility > International Initiatives

International Initiatives

Malaria Control

Paladin has provided funding support to research firm, Eastland Medical Systems Limited, which is developing a sub-lingual (under the tongue) applicator which could significantly improve the effectiveness of malaria treatment of young children, who are most susceptible to death from the disease. Preliminary trials indicate a 70% improvement in uptake in young children compared with medication provided in drug form. Eastland recently undertook a successful clinical trial in which 15 children with complicated malaria were treated against a comparator drug – iv quinine, the World Health Organisation recommended treatment, and achieved 100% clearance rate within 24-36 hours. A further 150-patient confirmative study is to be undertaken shortly.

HIV/AIDS Vaccine Research

Paladin is among leading mining companies supporting the clinical trial of an Australian-developed therapeutic treatment vaccine designed to aid in the fight against HIV/AIDS. The vaccine – called VIR201 – has been developed by the Australian firm, Virax Holdings Limited. Its recent clinical trial in South Africa used a more purified and higher dose of the VIR201 vaccine and Virax is anticipating that this would have the positive effect of promoting a stronger immune response. The trial was “double blinded”, with no results available to patients, investigators or Virax until reviewed by an independent data safety monitoring board.